Metastatic castration-resistant prostate cancer
Conditions
Brief summary
Tumor dose per treatment cycle (post-therapeutic dosimetry)
Detailed description
Tumor dose per treatment cycle (pre-therapeutic dosimetry), Absolute and percentage changes from baseline in tumor volume and SUV, Incidence, severity, seriousness, and relationship to study intervention of adverse events and serious adverse events; clinically significant changes in laboratory parameters, vital signs, and physical examination findings, Exploratory: Association between tumor absorbed dose and changes from baseline in tumor volume and SUV, Exploratory: Changes from baseline in PET kinetic parameters and blood-based biomarkers
Interventions
DRUG177LU-PSMA-I&T
Sponsors
Universitetssykehuset Nord-Norge HF
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor dose per treatment cycle (post-therapeutic dosimetry) | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor dose per treatment cycle (pre-therapeutic dosimetry), Absolute and percentage changes from baseline in tumor volume and SUV, Incidence, severity, seriousness, and relationship to study intervention of adverse events and serious adverse events; clinically significant changes in laboratory parameters, vital signs, and physical examination findings, Exploratory: Association between tumor absorbed dose and changes from baseline in tumor volume and SUV, Exploratory: Changes from baseline in PET kinetic parameters and blood-based biomarkers | — |
Outcome results
None listed